Perlecan Domain V Binding to Alpha2beta1 Integrin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyloidogenic diseases, such as Alzheimer's, fail to effectively address the synaptic and overt cell toxicity caused by Aβ peptides, particularly due to the inability to inhibit Aβ-mediated deposition and toxicity at the cellular level.
Innovation Solution
Administration of perlecan domain V (DV) or its fragments, which bind to α2β1 integrin, thereby competing with Aβ and reducing its toxic effects, potentially combined with antibodies targeting αv or β1 integrins to enhance inhibition of Aβ-mediated toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for amyloidogenic diseases, then the disease can be managed, but Aβ-mediated deposition and toxicity at the cellular level cannot be effectively inhibited
Solution Approach 1:
Perlecan domain V serves as an intermediary molecule that binds to α2β1 integrin, preventing Aβ from directly interacting with the integrin receptor. This mediator approach blocks the harmful Aβ-integrin interaction without requiring direct degradation or removal of Aβ, thereby effectively inhibiting Aβ-mediated deposition and toxicity at the cellular level
Solution Approach 2:
The invention extracts and utilizes only the functional domain V (85-kDa C-terminal domain) of perlecan, which contains the specific binding activity for α2β1 integrin. By using just this critical domain rather than the entire perlecan protein or other non-essential regions, the treatment achieves high specificity and effectiveness in blocking Aβ toxicity while minimizing unnecessary molecular complexity
2Reliability
If perlecan domain V binds to α2β1 integrin to inhibit Aβ toxicity, then Aβ-mediated toxicity is reduced, but the complexity of the therapeutic agent increases
Solution Approach 1:
The invention extracts and utilizes only the functional domain V (85-kDa C-terminal domain) of perlecan, which contains the specific binding activity for α2β1 integrin. By using just this critical domain rather than the entire perlecan protein or other non-essential regions, the treatment achieves high specificity and effectiveness in blocking Aβ toxicity while minimizing unnecessary molecular complexity
Solution Approach 2:
The perlecan protein is segmented into five distinct domains, and the invention specifically employs domain V for therapeutic purposes. This segmentation allows the therapeutic agent to be simplified to only the necessary functional region, reducing overall complexity while maintaining high efficacy in inhibiting Aβ-mediated toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of perlecan domain V and integrin-targeting antibodies effectively inhibits Aβ deposition and toxicity, providing a therapeutic approach to mitigate the progression of amyloidogenic diseases by reducing Aβ-induced neurotoxicity and deposition in neuronal cells.
Implementation Method 1
perlecan domain V (DV) or a fragment thereof, or a peptide having at least 85% sequence identity to SEQ ID NO:1 over a comparison window of at least 10 amino acids, wherein the fragment or peptide binds α2β1 integrin
Data Source
AI summary
The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.